Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Dendreon Humbled, Lessons Learned For Cancer Vaccine Makers

Executive Summary

Problems that led to the capsizing of Dendreon Corp.’s Provenge prostate cancer immunotherapy are particular to the company and product, some cancer vaccine makers are quick to say. Nevertheless, what the Street saw as a commercial disaster for the pioneering treatment bears lessons for those who follow in the budding space.

You may also be interested in...



Sponsors Drive CARs To The Next Destination: Pivotal Trials

With proof of high response rates in small studies of B-cell malignancies in the rear view, sponsors focus on the next hurdles – launching potentially registrational studies in 2015, honing plans for a smooth-running manufacturing process and branching out into new indications.

Juno Launches With Competing Immunotherapy Programs

The latest data from early cancer immunotherapy trials show patients in complete remission, reinforcing the field’s most-watched status. Juno Therapeutics is raising a war chest to capture programs from rival oncology research centers, but it doesn’t mean the competition has ended.

Embracing Rival Programs, Juno Ventures Forth With Talk Of Cancer Cure

The richly funded start-up is an unlikely collaboration between rival oncology research centers, both with immunotherapy programs that require complicated cell therapy processes. Coming together under one roof doesn’t mean the competition has ended.

Related Content

Topics

UsernamePublicRestriction

Register

PS053711

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel